| Benjamin Mark Frishberg, MD | |
|
6010 Hidden Valley Rd Ste 200, Carlsbad, CA 92011-4219 | |
| (760) 631-3000 | |
| (760) 631-3016 |
| Full Name | Benjamin Mark Frishberg |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 45 Years |
| Location | 6010 Hidden Valley Rd Ste 200, Carlsbad, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952346348 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0109X | Ophthalmology - Neuro-ophthalmology | G43493 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Scripps Memorial Hospital - Encinitas | Encinitas, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North County Neurology Associates Medical Group | 5193625911 | 34 |
News Archive
Researchers at the Johns Hopkins Bloomberg School of Public Health have signed a four-year agreement with Iasist of Barcelona, Spain, which will give Iasist distribution rights to the JHU Adjusted Clinical Groups® Case-Mix System (ACG System) in Spain and Portugal. Iasist is currently assisting the Basque National Health Service (Osakidetza) in using the ACG System to allocate resources among primary care clinics.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).
Stereotaxis, Inc. announced today that the underwriters for the recently announced public offering of Stereotaxis common stock have exercised in full their over-allotment option to purchase an additional 975,000 shares of the Company's common stock. The 7,475,000 shares of Stereotaxis common stock in the offering, including the 975,000 shares subject to the over-allotment option, are being sold at a price to the public of $4.00 per share.
New findings from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
› Verified 3 days ago
| Entity Name | North County Neurology Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558398842 PECOS PAC ID: 5193625911 Enrollment ID: O20040109000333 |
News Archive
Researchers at the Johns Hopkins Bloomberg School of Public Health have signed a four-year agreement with Iasist of Barcelona, Spain, which will give Iasist distribution rights to the JHU Adjusted Clinical Groups® Case-Mix System (ACG System) in Spain and Portugal. Iasist is currently assisting the Basque National Health Service (Osakidetza) in using the ACG System to allocate resources among primary care clinics.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).
Stereotaxis, Inc. announced today that the underwriters for the recently announced public offering of Stereotaxis common stock have exercised in full their over-allotment option to purchase an additional 975,000 shares of the Company's common stock. The 7,475,000 shares of Stereotaxis common stock in the offering, including the 975,000 shares subject to the over-allotment option, are being sold at a price to the public of $4.00 per share.
New findings from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin Mark Frishberg, MD 6010 Hidden Valley Rd Ste 200, Carlsbad, CA 92011-4219 Ph: (760) 631-3000 | Benjamin Mark Frishberg, MD 6010 Hidden Valley Rd Ste 200, Carlsbad, CA 92011-4219 Ph: (760) 631-3000 |
News Archive
Researchers at the Johns Hopkins Bloomberg School of Public Health have signed a four-year agreement with Iasist of Barcelona, Spain, which will give Iasist distribution rights to the JHU Adjusted Clinical Groups® Case-Mix System (ACG System) in Spain and Portugal. Iasist is currently assisting the Basque National Health Service (Osakidetza) in using the ACG System to allocate resources among primary care clinics.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).
Stereotaxis, Inc. announced today that the underwriters for the recently announced public offering of Stereotaxis common stock have exercised in full their over-allotment option to purchase an additional 975,000 shares of the Company's common stock. The 7,475,000 shares of Stereotaxis common stock in the offering, including the 975,000 shares subject to the over-allotment option, are being sold at a price to the public of $4.00 per share.
New findings from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
› Verified 3 days ago
Dr. Michael Kennedy Tracy, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6183 Paseo Del Norte Ste 290, Carlsbad, CA 92011 Phone: 760-603-9910 | |
Dr. Bill G Bell, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7040 Avenida Encinas, 110, Carlsbad, CA 92011 Phone: 760-931-0099 | |
Dr. Christopher Nawn Spellman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6221 Metropolitan St, Suite 200, Carlsbad, CA 92009 Phone: 760-799-3699 Fax: 760-633-3370 | |
Hasan Suha Ergin, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3925 Skyline Rd, Carlsbad, CA 92008 Phone: 760-803-8090 | |
Dr. John Davis Edmiston, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3480 Carlsbad Blvd, Suite A, Carlsbad, CA 92008 Phone: 916-765-9261 Fax: 858-429-9969 | |
Dr. Paul Hong-dze Chen, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1905 Calle Barcelona, Ste 208, Carlsbad, CA 92009 Phone: 760-930-9696 Fax: 760-930-9696 |